Is AOD-9604 Legal in Missouri? How to Access It Legally

What Is AOD-9604 and Why Do People Use It?

AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, specifically amino acids 176 to 191. Researchers designed it to reproduce the fat-metabolizing effects of growth hormone without the insulin-resistance or IGF-1-driven side effects seen with full-length hGH. The peptide stimulates lipolysis and inhibits lipogenesis through mechanisms that appear to be independent of the growth hormone receptor, acting instead via beta-adrenergic pathways in adipose tissue. [1]

Why Patients Seek It Out

Patients typically ask about AOD-9604 for one of three reasons: body-fat reduction alongside diet and exercise, adjunctive use with GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro), or cartilage and joint repair (a secondary research application studied in osteoarthritis models). The weight-loss application has the most clinical data, though that data remains limited to Phase II.

What the Phase II Evidence Actually Shows

The most cited human trial enrolled approximately 300 adults with obesity and tested subcutaneous AOD-9604 doses of 500 mcg daily over 12 weeks. Participants receiving 500 mcg lost a mean of 2.1 kg more than the placebo group. Those results, while statistically significant, are modest compared with semaglutide 2.4 mg, which produced 14.9% mean body-weight loss (roughly 15.3 kg) at 68 weeks in STEP-1 (N=1,961, P<0.001). [2] AOD-9604 never advanced to Phase III, which is one reason the FDA never approved it as a drug.

Federal Legal Status: The FDA Framework That Governs Missouri

Missouri does not have a separate state law targeting AOD-9604. That means the operative legal framework is entirely federal, and it has changed meaningfully in the past two years. Understanding three distinct federal designations is necessary before you can answer whether any pharmacy in Missouri can legally fill an AOD-9604 prescription today.

Designation 1: Not an FDA-Approved Drug

AOD-9604 has never received New Drug Application (NDA) or Biologics License Application (BLA) approval from the FDA. [3] Without approval, it cannot be marketed or sold as a finished pharmaceutical product in the United States by any manufacturer or distributor. This is the baseline federal position and is not in dispute.

Designation 2: GRAS Status for Food Use (2014)

In 2014 the FDA acknowledged GRAS Notice No. 000612, granting AOD-9604 Generally Recognized as Safe status as a food ingredient at specified concentrations. [4] This designation is frequently misread as a form of drug approval. It is not. GRAS applies to food-additive safety, not to the safety or efficacy of a substance used as an injectable pharmaceutical. Citing GRAS status as proof of legality for subcutaneous injection is scientifically incorrect.

Designation 3: Removal from the 503A Bulk Substances List (2024)

This is the most consequential recent development. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, state-licensed compounding pharmacies can use bulk drug substances to prepare individualized preparations for specific patients, provided the substance appears on the FDA's "503A bulks list" or meets certain other criteria. [5] The FDA's 2024 final rule on bulk drug substances for 503A compounding removed AOD-9604 from the category of substances that may be used. The agency's evaluation found insufficient evidence of clinical use and unresolved questions about safety when administered by injection. [6]

For 503B outsourcing facilities (larger compounding operations that can produce drug products for office stock without patient-specific prescriptions), AOD-9604 was never on the permitted bulks list, so that pathway has always been closed.

Missouri State Law: What the Missouri Board of Pharmacy and Medical Practice Act Say

Missouri regulates pharmacy practice under Title XXII, Chapter 338 of the Missouri Revised Statutes and medical practice under Chapter 334. Neither chapter contains a specific enumerated prohibition on AOD-9604 by name. [7] This matters for two reasons.

First, a Missouri-licensed physician retains legal authority under the Medical Practice Act to prescribe any substance for a patient for a legitimate medical purpose, including off-label or investigational use, as long as that prescription is within the standard of care and the substance itself is not a controlled substance under the Missouri Controlled Substances Act (Chapter 195). AOD-9604 is not a scheduled controlled substance in Missouri or under the federal DEA schedule. [8]

Second, the Missouri Board of Pharmacy follows federal USP and FDA standards for compounding. Because the 2024 federal rule restricts 503A compounding of AOD-9604, a Missouri compounding pharmacy that fills such a prescription may be subject to federal enforcement action, even if no specific Missouri statute makes the act a state-level crime.

What This Means for the Patient

A Missouri patient who obtains AOD-9604 does not personally violate any clearly defined criminal statute simply by possessing it. The legal risk falls primarily on the dispensing pharmacy, not the individual. Purchasing AOD-9604 from unregulated online vendors, research chemical suppliers, or international sources introduces product safety risks (contamination, incorrect dosing, no sterility testing) that are entirely separate from the legal question.

What This Means for the Prescribing Physician

A Missouri physician who prescribes AOD-9604 should document medical necessity thoroughly and should verify in writing that the compounding pharmacy being used has current legal authority to dispense the substance. The Federation of State Medical Boards has noted that prescribing outside evidence-based guidelines requires careful documentation to demonstrate that the prescriber acted within the standard of care. [9]

The 503A/503B Compounding Distinction: A Practical Guide for Missouri Patients

The two compounding pathways operate under different rules, and Missouri patients need to understand both before contacting a pharmacy.

503A Pharmacies: State-Licensed, Patient-Specific

A 503A pharmacy compounds drugs for specific patients based on a valid prescription from a licensed practitioner. Before the 2024 FDA final rule, AOD-9604 appeared on the interim list of substances under evaluation, which allowed some 503A pharmacies to continue compounding it. After the rule, that permissive interim status ended for AOD-9604. A 503A pharmacy in Missouri that continues to compound AOD-9604 is doing so outside the current federal framework.

Some pharmacies argue that a substance not yet explicitly prohibited by name in every regulatory document retains a gray-area status. That argument is legally thin after a final rule, but it explains why some telehealth services continue to offer AOD-9604 prescriptions as of early 2025. Patients should ask any prescribing telehealth service to produce, in writing, the name and FDA registration number of the compounding pharmacy they use, and to confirm that pharmacy's legal basis for compounding AOD-9604 specifically.

503B Outsourcing Facilities: Bulk Production, No Patient Script Needed

A 503B facility can produce larger batches for healthcare providers without individual prescriptions, but only from substances on the FDA's 503B bulks list. AOD-9604 has never appeared on that list. No Missouri or out-of-state 503B facility can lawfully compound AOD-9604 for commercial distribution. [5]

Practical Checklist Before You Fill a Prescription

Ask your telehealth provider or pharmacist these four questions:

• Is the compounding pharmacy a licensed 503A facility registered with the Missouri Board of Pharmacy?
• Can the pharmacy provide documentation of its legal basis for compounding AOD-9604 after the 2024 FDA final rule?
• Does the pharmacy perform USP 797 sterility testing on injectable preparations?
• Is the product dispensed with a certificate of analysis from an independent third-party lab?

If any answer is "no" or "we cannot share that," treat it as a red flag.

Clinical Evidence: What Research Actually Supports

The clinical record for AOD-9604 is shorter than many peptide vendors acknowledge. Here is what peer-reviewed sources and trial registries show.

Phase I Safety Data

Phase I studies established that AOD-9604 administered subcutaneously at doses up to 1,000 mcg daily was well-tolerated in healthy adults, with no significant changes in blood glucose, insulin, or IGF-1 levels. [1] This tolerability profile was one reason researchers and compounding pharmacies viewed it as a lower-risk peptide compared with growth hormone itself.

Phase II Weight-Loss Trials

Multiple Phase II studies tested AOD-9604 in adults with obesity. The 500 mcg subcutaneous daily dose consistently produced greater fat mass reduction than placebo over 12 weeks, with the most cited trial showing the 2.1 kg advantage noted above. [10] The developer (Metabolic Pharmaceuticals, Australia) halted Phase III development after the Phase II results were considered insufficient to justify the investment against a high regulatory bar.

Cartilage and Joint Data

Animal studies published in peer-reviewed journals have shown that AOD-9604 promotes cartilage regeneration and may reduce articular cartilage degradation in osteoarthritis models. [11] Human clinical data for this application remain absent as of this writing. Any clinical claim beyond the Phase II weight-loss data should be treated with appropriate skepticism.

What the FDA's Own Evaluation Found

The FDA's 2023 evaluation document (released before the 2024 final rule) stated that AOD-9604 lacks sufficient evidence of a clinical need that could not be met by an approved drug, and that data on injectable-use safety in humans is limited. The agency noted that "the available evidence does not demonstrate that this bulk drug substance is necessary for the preparation of a compounded drug product." [6] That language is worth reading directly, not paraphrased.

How to Get AOD-9604 Legally in Missouri: Step-by-Step

Given the regulatory constraints, the following sequence represents the most defensible legal path for a Missouri resident seeking AOD-9604.

Step 1: Consult a Missouri-Licensed Physician or Telehealth Provider

Schedule a consultation with a physician licensed in Missouri who has documented experience with peptide therapy. The physician should take a full history, review relevant labs (fasting glucose, IGF-1, CBC, metabolic panel), and determine whether AOD-9604 is medically appropriate for your specific situation. A prescription issued without a clinical evaluation is not defensible under either the Missouri Medical Practice Act or the standard of care.

Step 2: Verify the Compounding Pharmacy

Ask for the pharmacy name, state license number, and their written position on compounding AOD-9604 after the 2024 FDA rule. Cross-reference the pharmacy license on the Missouri Board of Pharmacy license verification portal and the FDA's drug compounding registration database at fda.gov. [3]

Step 3: Request a Certificate of Analysis

Any legitimate compounding pharmacy will provide a certificate of analysis (COA) from a third-party lab confirming peptide purity, concentration, and sterility. A COA from the pharmacy's own lab is less reliable than one from an independent testing facility.

Step 4: Use Proper Administration Protocol

If the prescription is filled, follow the prescribing physician's injection protocol exactly. Typical subcutaneous dosing studied in trials was 500 mcg daily, administered in the morning in a fasted state. Do not exceed the prescribed dose, and report any injection-site reactions or systemic symptoms promptly.

Step 5: Monitor with Follow-Up Labs

A responsible prescriber will order follow-up labs at 6 and 12 weeks, at minimum. Relevant markers include fasting glucose, IGF-1, body composition (DEXA or BIA), and any baseline abnormalities identified in Step 1.

Telehealth Access in Missouri: What Is and Is Not Permitted

Missouri adopted telehealth parity rules under SB 1096 (2020), which require insurers to cover telehealth services on par with in-person care for covered services. [12] A telehealth physician practicing in Missouri must hold a Missouri medical license or qualify under interstate compact rules. The Ryan Haight Online Pharmacy Consumer Protection Act requires that a prescriber either conduct at least one in-person medical evaluation or operate under a DEA-registered telemedicine platform for controlled substances. AOD-9604 is not a controlled substance, so the Ryan Haight Act's in-person requirement does not technically apply. Still, a telehealth prescriber who never reviews labs or takes a history is practicing below the standard of care regardless of the legal technicality.

The Missouri Board of Registration for the Healing Arts has stated that prescribing outside an established patient-physician relationship, even for non-controlled substances, may constitute unprofessional conduct under 334.100.2(4) RSMo. [13]

Comparing AOD-9604 with FDA-Approved Alternatives

Patients considering AOD-9604 for weight loss should understand how it compares, in clinical terms, with the approved options available through any licensed Missouri prescriber.

| Therapy | FDA Status | Mean Weight Loss | Trial Duration | Missouri Access | |---|---|---|---|---| | Semaglutide 2.4 mg (Wegovy) | Approved | 14.9% body weight [2] | 68 weeks | Standard prescription | | Tirzepatide 15 mg (Zepbound) | Approved | 20.9% body weight [14] | 72 weeks | Standard prescription | | AOD-9604 500 mcg SQ | Not approved | ~2.1 kg vs placebo | 12 weeks | Legally restricted (2024) | | Tesamorelin (Egrifta) | Approved (HIV lipodystrophy) | HIV-specific indication | 26 weeks | Off-label use possible |

The comparison is not designed to discourage AOD-9604 use categorically. Patients who have failed or cannot tolerate GLP-1 agonists may have a physician-documented rationale for exploring peptide options. The point is that the clinical evidence gap between approved and unapproved options is large, and Missouri patients deserve to see that data clearly before making a decision.

Risks of Purchasing AOD-9604 Outside Legal Channels

Unregulated AOD-9604 sold as a "research chemical" or via offshore pharmacy websites carries risks that extend well beyond the legal question.

A 2020 analysis of peptides purchased from unregulated online vendors found that 42% of samples failed purity testing, with common contaminants including bacterial endotoxins and incorrect peptide sequences. [15] Injecting a contaminated preparation subcutaneously can cause local abscess formation, systemic infection, or anaphylaxis. No malpractice protection exists if a patient self-administers a product obtained outside a licensed pharmacy, and no physician oversight means adverse events may go unrecognized.

Missouri residents who purchase AOD-9604 from gray-market research vendors also accept unknown legal exposure if the FDA's enforcement priorities shift. The agency has issued warning letters to peptide vendors in the past and has broad authority to seize unapproved drug products in interstate commerce. [3]